Ultragenyx Analyst & Investor Day

December 4, 2017

Ultragenyx management will review development progress and commercial readiness, and outside experts will share their perspectives.

Register for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Ultragenyx Pharmaceutical, Inc. [RARE] US$3,255 MM MCap
Biotech­nol­o­gy com­pany based in No­va­to, CA found­ed by the former CMO of Bio­Marin. The com­pany is fo­cus­ing on de­vel­op­ing pro­tein or small molecule ther­a­pies for rare ge­net­ic di­s­or­ders. Ul­tragenyx will choose prod­uct can­di­dates with clear bi­ol­o­gy and dis­eas­es with high un­met med­i­cal need and ap­p­ly , and rapid and ef­fi­cient de­vel­op­ment strate­gies. . [more in­for­ma­tion]

Event Contact

Brooks Rahmer
Solebury Trout